LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Search

Charles River Laboratories International Inc

Закрыт

СекторЗдравоохранение

168.66 -1.6

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

167.72

Макс.

174.52

Ключевые показатели

By Trading Economics

Доход

2.9M

56M

Продажи

-27M

1B

P/E

Средняя по отрасли

592.3

105.69

Прибыль на акцию

2.43

Рентабельность продаж

5.529

Сотрудники

18,700

EBITDA

-23M

198M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+11.95% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-487M

8.3B

Предыдущая цена открытия

170.26

Предыдущая цена закрытия

168.66

Новостные настроения

By Acuity

21%

79%

49 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Strong Bullish Evidence

Charles River Laboratories International Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

13 нояб. 2025 г., 21:34 UTC

Отчет

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 нояб. 2025 г., 23:45 UTC

Обсуждения рынка

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 нояб. 2025 г., 23:42 UTC

Приобретения, слияния, поглощения

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 нояб. 2025 г., 23:41 UTC

Обсуждения рынка

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 нояб. 2025 г., 23:24 UTC

Отчет

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 нояб. 2025 г., 23:24 UTC

Отчет

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 нояб. 2025 г., 23:23 UTC

Отчет

JBS NV 3Q EPS 52c >JBS

13 нояб. 2025 г., 23:23 UTC

Отчет

JBS NV 3Q Sales $22.6B >JBS

13 нояб. 2025 г., 23:04 UTC

Обсуждения рынка

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 нояб. 2025 г., 22:02 UTC

Отчет

Nu Holdings 3Q Net $783M >NU

13 нояб. 2025 г., 22:01 UTC

Отчет

Nu Holdings 3Q Rev $4.2B >NU

13 нояб. 2025 г., 21:51 UTC

Приобретения, слияния, поглощения

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 нояб. 2025 г., 21:50 UTC

Отчет

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 нояб. 2025 г., 21:45 UTC

Приобретения, слияния, поглощения

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 нояб. 2025 г., 21:41 UTC

Приобретения, слияния, поглощения

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 нояб. 2025 г., 21:36 UTC

Приобретения, слияния, поглощения

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 нояб. 2025 г., 21:36 UTC

Приобретения, слияния, поглощения

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 нояб. 2025 г., 21:36 UTC

Приобретения, слияния, поглощения

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 нояб. 2025 г., 21:36 UTC

Приобретения, слияния, поглощения

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 нояб. 2025 г., 21:36 UTC

Приобретения, слияния, поглощения

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 нояб. 2025 г., 21:33 UTC

Обсуждения рынка

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 нояб. 2025 г., 21:33 UTC

Отчет

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 нояб. 2025 г., 21:31 UTC

Отчет

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 нояб. 2025 г., 21:25 UTC

Отчет

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 нояб. 2025 г., 21:25 UTC

Отчет

Figure Tech Solutions 3Q EPS 34c >FIGR

13 нояб. 2025 г., 21:23 UTC

Отчет

Intchains Group 3Q Rev $1.3M >ICG

13 нояб. 2025 г., 21:03 UTC

Отчет

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 нояб. 2025 г., 21:02 UTC

Отчет

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 нояб. 2025 г., 21:01 UTC

Отчет

Applied Materials 4Q Rev $6.8B >AMAT

13 нояб. 2025 г., 21:01 UTC

Отчет

Applied Materials 4Q Gross Margin 48.0% >AMAT

Сравнение c конкурентами

Изменение цены

Charles River Laboratories International Inc Прогноз

Целевая цена

By TipRanks

11.95% рост

Прогноз на 12 месяцев

Средняя 192 USD  11.95%

Максимум 225 USD

Минимум 165 USD

Основано на мнении 12 аналитиков Wall Street, спрогнозировавших целевые цены для Charles River Laboratories International Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

12 ratings

6

Покупка

6

Удержание

0

Продажа

Техническая оценка

By Trading Central

117.16 / 144.77Поддержка и Сопротивление

Краткосрочная

Strong Bullish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

49 / 374Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat